ClinicalTrials.gg
RecruitingNCT05008185Updated Nov 29, 2024

Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation

An observational study in Neuroma, sponsored by Medstar Health Research Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Medstar Health Research Institute · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Neuroma with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Neuroma · United States.

Started
2021
with 1 other
Observational
7 of 25
1 open now
Registered
20th of 25
by date

Among the 25 studies in Neuroma with a site in United States, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 20th registered.

Neuroma

55 studies on the registry are indexed under Neuroma; 10 are open to participants now.

Browse Neuroma studies →

Open to participants now

4 of the 25 studies in Neuroma with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Neuroma studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Neuroma with a site in United States, or all of them as a file.
02

Study summary

This study is being done to demonstrate the effectiveness of Regenerative Peripheral Nerve Interfaces (RPNI) surgery in treating symptomatic neuromas of the hand and digits following amputation compared to standard of care using a Prospective, Observational Trial

Read the detailed description

This will be a prospective observational study that seeks to provide a comprehensive assessment of the outcomes after RPNI surgery compared to standard of care by utilizing multiple established and validated patient-reported outcomes measures, carefully tracking pre- and post-operative pain regimens, and performing functional and physiologic tests.

03

Conditions studied

  • Neuroma

Browse trials for

Keywords

  • Neuroma
  • Neuroma Pain
  • Finger Amputation
  • Hand Amputation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients 18 years or older with a history of digit, multi-digit or partial hand amputation. Patients must have discrete neuroma pain on clinical exam.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • History of unilateral digit, multiple digit, or partial hand amputation
  • Discrete neuroma pain on clinical exam
  • Following standard of care (SOC), confirmation through a local block and/or ultrasound imaging will be performed if indicated
  • Must be seen by a hand therapist for at least 6-week trial of desensitization therapy

Exclusion criteria

Exclusion Criteria:

  • Patients with previous surgical treatment for symptomatic neuromas of the digits or hand
  • Patients with other major injuries more proximal in the ipsilateral extremity that cause chronic pain or functional loss
  • women pregnant at time of enrollment
  • prisoners
  • adults who are unable to consent
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Regenerative Peripheral Nerve Interface

    symptomatic neuroma is excised, and the end of the peripheral nerve is implanted into a small denervated free muscle graft harvested from the patient

    Procedure: Regenerative Peripheral Nerve Interface (RPNI) surgery

  • Traction Neurectomy

    simple excision and traction neurectomy

    Procedure: Traction Neurectomy

Interventions

  • ProcedureRegenerative Peripheral Nerve Interface (RPNI) surgery

    Surgeons will perform neuroma resection and RPNI creation using a free muscle graft from the brachioradialis muscle harvested through a small separate incision

  • ProcedureTraction Neurectomy

    Surgeons will perform neuroma resection and traction neurectomy,

06

What researchers measure

Primary outcomes

  1. Patient-Reported Outcomes Measurement Information System - Pain Interference (PROMIS-PI)

    PROMIS Pain Interference (PROMIS-PI) scale measures the extent to which pain hinders an individual's engagement with physical, mental, cognitive, emotional, recreational, and social activities over the past 7 days answering each questions with a response of not at all, a little bit, somewhat, quite a bit, and very much with not at all being the best and very much the worst.

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

  2. Short-form McGill Pain Questionnaire (SF-MPQ-2)

    theShort-form McGill Pain Questionnaire (SF-MPQ-2) measures 24 different qualities of pain and related symptoms using the intensity of pain and related symptoms felt during the past week on 0 to 10 scale, with 0 being no pain and 10 being the worst pain .

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

  3. PROMIS Global Health (GH) v1.2

    The Global Health Questionnaire contains 10 questions (7 general and 3 about the last 7 days). First 7 questions use a scale of excellent, very good, good, fair, and poor, poor being the worst with excellent being the best. The other three questions use different scales such as; never rarely, sometimes, often or always with never being the best and always being the worst; as well as none, mild, moderate, severe, very severe with none being the best and very severe being the worst; finally pain rating numbered 0-10 with 0 being no pain and 10 being the worst pain imaginable.

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

  4. Patient Health Questionnaire (PHQ-9),

    The PHQ-9 form is a brief, self-administered questionnaire that assesses depression symptoms over the last 2 weeks consisting of 10 questions. 9 will be answered on a scale of 0-3 with 0 being the best and 3 bing the worst. The last question will use a response of not difficult at all, somewhat difficult, very difficult, and extremely difficult with not difficult at all being the best and extremely difficult being the worst.

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

  5. Generalized Anxiety Disorder measure (GAD-7),

    Generalized Anxiety Disorder measure (GAD-7) is a screening tool and severity measure for generalised anxiety disorder (GAD) over the past 2 weeks consisting of 7 questions answered on a scale of 0-3 with 0 being the best and 3 being the worst.

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

  6. PC-PTSD-5

    The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) is a 5-item screening tool with 'Yes/No" answers designed to identify individuals with probable PTSD. Yes" answers represent the worst and "no" represents the best.

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

Secondary outcomes

  1. PROMIS UpperExtremity (UE)

    PROMIS UpperExtremity (UE) is designed to evaluate upper extremity function using a scale of 1-5 with 5 being the best possible answer and 1 being the worst.

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

  2. Brief Michigan Hand Outcomes Questionnaire (bMHQ)

    The Brief Michigan Hand Outcomes Questionnaire (bMHQ) evaluates six upper extremity domains of function, activities of daily living(ADLs), aesthetics, performance,pain,and satisfaction using a scale of 1-5 with 5 being the best possible answer and 1 being the worst.

    Time frame: Assessing change from Baseline to 1 week, 1 month, 3 months and 6 months

  3. Grip Strength

    A standard dynamometer will be used to evaluate grip strength

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  4. Pinch Strength -Key and Three-point

    Evaluate key pinch (thumb to radial border of index) and three-point pinch (index, middle, and thumb tips) strength.

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  5. Range of Motion

    Evaluate active and passive range of motion of all joints in the affected extremity proximal to the amputation stump, total active and passive range of motion of all unaffected digits on the ipsilateral hand, and total active motion of fall digits and wrist on the contralateral hand as an internal control

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  6. Fine Motor Function - 9-Hole Peg Test (9HPT)

    Evaluate timed exercise during which nine relatively small pegs are picked up, one at a time, and put into nine corresponding holes. The pegs are then removed from the holes (one at a time) and placed back in the starting bin.

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  7. FunctionalTask Testing - Lifting boxes

    Evaluate whether the participant is able to perform the task, grip that was used, maximum weight used, and any compensatory findings. Subjects will be asked their pain level during each lift using a 10-point numerical scale

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  8. Functional Task Testing - Carrying Boxes

    Evaluate whether the participant is able to perform the task, grip that was used, maximum weight used, and any compensatory findings. Subjects will be asked their pain level during each lift using a 10-point numerical scale

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  9. Functional Task Testing - Push/Pull sled

    Evaluate whether the participant is able to perform the task, grip that was used, maximum weight used, and any compensatory findings. Subjects will be asked their pain level during each lift using a 10-point numerical scale

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  10. Functional Task Testing - Hammer

    Evaluate tolerance for vibration and grip to perform a hammer task using

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  11. Functional Task Testing - Vice Grip

    Evaluate vice grip Strength with all available digits using the Baltimore Therapeutic Equipment (BTE) PrimusRS work simulator.

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  12. Functional Task Testing - Gear Shifting

    Evaluate ability to grip, push and pull gear shift with all available digits using the Baltimore Therapeutic Equipment (BTE) PrimusRS work simulator

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

  13. Functional Task Testing - Weapon Recoil

    Evaluate the ability to preform this simulated task using the Baltimore Therapeutic Equipment (BTE) PrimusRS work simulator

    Time frame: Assessing change from Baseline to 1 month, 3 months and 6 months

07

Study locations

1 of 2 sites recruiting
  • The Curtis National Hand Center at Medstar Union Memorial Hospital
    Baltimore, Maryland 21218, United States
    Recruiting
  • University of Michigan Plastic Surgery
    Ann Arbor, Michigan 48109, United States
    Not yet recruiting
    • Jenni Hammill, M.P.H · Contactjenberry@med.umich.edu · 570-559-7912
    • Theodore A Kung, MD · Principal investigator
08

References and documents

Publications

  • Woo SL, Kung TA, Brown DL, Leonard JA, Kelly BM, Cederna PS. Regenerative Peripheral Nerve Interfaces for the Treatment of Postamputation Neuroma Pain: A Pilot Study. Plast Reconstr Surg Glob Open. 2016 Dec 27;4(12):e1038. doi: 10.1097/GOX.0000000000001038. eCollection 2016 Dec. PubMed 28293490 ↗
  • Urbanchek MG, Kung TA, Frost CM, Martin DC, Larkin LM, Wollstein A, Cederna PS. Development of a Regenerative Peripheral Nerve Interface for Control of a Neuroprosthetic Limb. Biomed Res Int. 2016;2016:5726730. doi: 10.1155/2016/5726730. Epub 2016 May 17. PubMed 27294122 ↗
  • Santosa KB, Oliver JD, Cederna PS, Kung TA. Regenerative Peripheral Nerve Interfaces for Prevention and Management of Neuromas. Clin Plast Surg. 2020 Apr;47(2):311-321. doi: 10.1016/j.cps.2020.01.004. Epub 2020 Feb 1. PubMed 32115057 ↗
  • Kemp SW, Cederna PS, Midha R. Comparative outcome measures in peripheral regeneration studies. Exp Neurol. 2017 Jan;287(Pt 3):348-357. doi: 10.1016/j.expneurol.2016.04.011. Epub 2016 Apr 17. PubMed 27094121 ↗
  • Ursu DC, Urbanchek MG, Nedic A, Cederna PS, Gillespie RB. In vivo characterization of regenerative peripheral nerve interface function. J Neural Eng. 2016 Apr;13(2):026012. doi: 10.1088/1741-2560/13/2/026012. Epub 2016 Feb 9. PubMed 26859115 ↗
  • Giladi AM, McGlinn EP, Shauver MJ, Voice TP, Chung KC. Measuring outcomes and determining long-term disability after revision amputation for treatment of traumatic finger and thumb amputation injuries. Plast Reconstr Surg. 2014 Nov;134(5):746e-755e. doi: 10.1097/PRS.0000000000000591. PubMed 25347649 ↗
  • Langhals NB, Woo SL, Moon JD, Larson JV, Leach MK, Cederna PS, Urbanchek MG. Electrically stimulated signals from a long-term Regenerative Peripheral Nerve Interface. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:1989-92. doi: 10.1109/EMBC.2014.6944004. PubMed 25570372 ↗
  • Frost CM, Cederna PS, Martin DC, Shim BS, Urbanchek MG. Decellular biological scaffold polymerized with PEDOT for improving peripheral nerve interface charge transfer. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:422-5. doi: 10.1109/EMBC.2014.6943618. PubMed 25569986 ↗
  • Woo SL, Urbanchek MG, Cederna PS, Langhals NB. Revisiting nonvascularized partial muscle grafts: a novel use for prosthetic control. Plast Reconstr Surg. 2014 Aug;134(2):344e-346e. doi: 10.1097/PRS.0000000000000317. No abstract available. PubMed 25068369 ↗
  • Kung TA, Langhals NB, Martin DC, Johnson PJ, Cederna PS, Urbanchek MG. Regenerative peripheral nerve interface viability and signal transduction with an implanted electrode. Plast Reconstr Surg. 2014 Jun;133(6):1380-1394. doi: 10.1097/PRS.0000000000000168. PubMed 24867721 ↗
  • Kung TA, Bueno RA, Alkhalefah GK, Langhals NB, Urbanchek MG, Cederna PS. Innovations in prosthetic interfaces for the upper extremity. Plast Reconstr Surg. 2013 Dec;132(6):1515-1523. doi: 10.1097/PRS.0b013e3182a97e5f. PubMed 24281580 ↗
  • Hooper RC, Cederna PS, Brown DL, Haase SC, Waljee JF, Egeland BM, Kelley BP, Kung TA. Regenerative Peripheral Nerve Interfaces for the Management of Symptomatic Hand and Digital Neuromas. Plast Reconstr Surg Glob Open. 2020 Jun 4;8(6):e2792. doi: 10.1097/GOX.0000000000002792. eCollection 2020 Jun. PubMed 32766027 ↗
  • Svientek SR, Ursu DC, Cederna PS, Kemp SWP. Fabrication of the Composite Regenerative Peripheral Nerve Interface (C-RPNI) in the Adult Rat. J Vis Exp. 2020 Feb 25;(156):10.3791/60841. doi: 10.3791/60841. PubMed 32176203 ↗
  • Vu PP, Vaskov AK, Irwin ZT, Henning PT, Lueders DR, Laidlaw AT, Davis AJ, Nu CS, Gates DH, Gillespie RB, Kemp SWP, Kung TA, Chestek CA, Cederna PS. A regenerative peripheral nerve interface allows real-time control of an artificial hand in upper limb amputees. Sci Transl Med. 2020 Mar 4;12(533):eaay2857. doi: 10.1126/scitranslmed.aay2857. PubMed 32132217 ↗
  • Frost CM, Ursu DC, Flattery SM, Nedic A, Hassett CA, Moon JD, Buchanan PJ, Brent Gillespie R, Kung TA, Kemp SWP, Cederna PS, Urbanchek MG. Regenerative peripheral nerve interfaces for real-time, proportional control of a Neuroprosthetic hand. J Neuroeng Rehabil. 2018 Nov 20;15(1):108. doi: 10.1186/s12984-018-0452-1. PubMed 30458876 ↗
  • Vu PP, Irwin ZT, Bullard AJ, Ambani SW, Sando IC, Urbanchek MG, Cederna PS, Chestek CA. Closed-Loop Continuous Hand Control via Chronic Recording of Regenerative Peripheral Nerve Interfaces. IEEE Trans Neural Syst Rehabil Eng. 2018 Feb;26(2):515-526. doi: 10.1109/TNSRE.2017.2772961. PubMed 29432117 ↗
  • Ursu D, Nedic A, Urbanchek M, Cederna P, Gillespie RB. Adjacent regenerative peripheral nerve interfaces produce phase-antagonist signals during voluntary walking in rats. J Neuroeng Rehabil. 2017 Apr 24;14(1):33. doi: 10.1186/s12984-017-0243-0. PubMed 28438166 ↗
  • Hart SE, Kung TA. Novel Approaches to Reduce Symptomatic Neuroma Pain After Limb Amputation. Curr Phys Med Rehabil Rep. 2020 Jun 16;(8):83-91.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Aug 2025, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2021
First posted
Aug 17, 2021
StartActual
Oct 5, 2021
Primary completionEst.
Aug 2025
CompletionEst.
Aug 2025
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05008185
Collaborators
United States Department of Defense, University of Michigan
Responsible party
Sponsor
First posted
Aug 17, 2021
Start date
Oct 5, 2021
Primary completion
Aug 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Nov 29, 2024

Study contacts

Isaac C Fleming
Contact
ike.c.fleming@medstar.net
410-554-2486
Aviram M Giladi, MS, MD
principal investigator · Medstar Union Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion